These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37233875)

  • 21. Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers.
    Peters E; Heuberger JAAC; Tiessen R; van Elsas A; Masereeuw R; Arend J; Stevens J; Pickkers P
    Clin Pharmacokinet; 2016 Oct; 55(10):1227-1237. PubMed ID: 27147514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects.
    Hernández-Mitre MP; Wallis SC; Morgan EE; Dudley MN; Loutit JS; Griffith DC; Roberts JA
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0109923. PubMed ID: 38059635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
    Han K; Cremer J; Elston R; Oliver S; Baptiste-Brown S; Chen S; Gardiner D; Davies M; Saunders J; Hamatake R; Losos J; Leivers M; Hood S; van der Berg F; Paff M; Ritter JM; Theodore D
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):790-801. PubMed ID: 30861337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
    Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Yogaratnam J
    Adv Ther; 2019 Sep; 36(9):2450-2462. PubMed ID: 31267367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers.
    Wallace M; White A; Grako KA; Lane R; Cato AJ; Snodgrass HR
    Scand J Pain; 2017 Oct; 17():243-251. PubMed ID: 29229209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.
    Cuvier V; Lorch U; Witte S; Olivier A; Gibot S; Delor I; Garaud JJ; Derive M; Salcedo-Magguilli M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2270-2279. PubMed ID: 29885068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
    Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
    J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
    Jansen M; Warrington S; Dishy V; Ohwada S; Johnson L; Brown K; Ishizuka H
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):661-669. PubMed ID: 29663714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
    Li X; Liu Y; Yao H; Wang M; Gao L; Lou J; Mao J; Wu W; Zhou Y; Tang Y; Yan W; Hu Y; Ding C; Chen S; Niu J; Ding Y
    Antimicrob Agents Chemother; 2022 May; 66(5):e0009422. PubMed ID: 35404074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design.
    Wu M; Li C; Zhang H; Sun J; Zhu X; Li X; Gao X; Wang W; Ding Y
    CNS Drugs; 2020 Aug; 34(8):867-877. PubMed ID: 32700191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
    Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
    Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.
    Xiao F; Zhang F; Zhang LL; Wei W
    Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study.
    Liu Y; Tan Y; Wei G; Lu Z; Liu Y; Yang B; Hui AM; Li K
    Pulm Pharmacol Ther; 2022 Jun; 73-74():102132. PubMed ID: 35595003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
    Nagy CF; Leach TS; Hoffman JH; Czech A; Carpenter SE; Guttendorf R
    Clin Ther; 2016 Sep; 38(9):2083-2097.e7. PubMed ID: 27568215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
    Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
    Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.